PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cocktail of drugs takes on tough pancreatic cancer
Disease control Not yet recruitingThis early-phase trial tests whether adding three experimental drugs (nogapendekin alfa inbakicept, sotevtamab, and zabadinostat) to standard chemotherapy can safely shrink pancreatic tumors that are borderline removable or locally advanced. About 30 adults with pancreatic cancer…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New hope for tough pancreatic cancer: targeted drug trial launches
Disease control Not yet recruitingThis study tests a drug called lorigerlimab in people with advanced pancreatic cancer that has a specific genetic makeup (BRCA, PALB2, or RAD51C/D mutations). The goal is to see if the drug can shrink tumors. About 40 adults will take part, and the study is not yet recruiting.
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC
-
New pill shows promise against tough cancers
Disease control Not yet recruitingThis study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug works by blocking a protein that helps tumors grow. The goal is to see if it is safe and can shrink or slow the cancer. About 219 adults wil…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: TYK Medicines, Inc • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
Can early gene testing unlock better cancer treatments?
Knowledge-focused Not yet recruitingThis study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:11 UTC